Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Cremonesi M, et al. Among authors: botta f. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514 Free PMC article. Review.
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E. Chiesa C, et al. Among authors: botta f. Cancer Biother Radiopharm. 2007 Feb;22(1):113-20. doi: 10.1089/cbr.2007.302. Cancer Biother Radiopharm. 2007. PMID: 17627419 Clinical Trial.
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Chiesa C, et al. Among authors: botta f. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20. Eur J Nucl Med Mol Imaging. 2009. PMID: 19455328 Clinical Trial.
Dosimetry for treatment with radiolabelled somatostatin analogues. A review.
Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, Rossi A, Bartolomei M, Mei R, Severi S, Salvatori M, Pedroli G, Paganelli G. Cremonesi M, et al. Among authors: botta f. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):37-51. Q J Nucl Med Mol Imaging. 2010. PMID: 20168285 Free article. Review.
Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors.
Pedicini P, Caivano R, Jereczek-Fossa BA, Strigari L, Vischioni B, Alterio D, Cremonesi M, Botta F, Nappi A, Improta G, Storto G, Benassi M, Orecchia R. Pedicini P, et al. Among authors: botta f. Theor Biol Med Model. 2012 Jun 19;9:23. doi: 10.1186/1742-4682-9-23. Theor Biol Med Model. 2012. PMID: 22713695 Free PMC article.
171 results